Trends in Cancer Immunotherapy
Modulation of the immune system for therapeutic ends has a long history, stretching back to Edward Jenner's use of cowpox to induce immunity to smallpox in 1796. Since then, immunotherapy, in the form of prophylactic and therapeutic vaccines, has enabled doctors to treat and prevent a variety o...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S4795 |
id |
doaj-8893da8a101341138ec59d1571cf4e3a |
---|---|
record_format |
Article |
spelling |
doaj-8893da8a101341138ec59d1571cf4e3a2020-11-25T02:22:15ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492010-01-01410.4137/CMO.S4795Trends in Cancer ImmunotherapyJoseph F. Murphy0Department of Surgery, Trinity Centre for Health Sciences, Adelaide and Meath incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.Modulation of the immune system for therapeutic ends has a long history, stretching back to Edward Jenner's use of cowpox to induce immunity to smallpox in 1796. Since then, immunotherapy, in the form of prophylactic and therapeutic vaccines, has enabled doctors to treat and prevent a variety of infectious diseases, including cholera, poliomyelitis, diphtheria, measles and mumps. Immunotherapy is now increasingly being applied to oncology. Cancer immunotherapy attempts to harness the power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for cancer immunotherapy is to apply advances in cellular and molecular immunology and develop strategies that effectively and safely augment antitumor responses.https://doi.org/10.4137/CMO.S4795 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joseph F. Murphy |
spellingShingle |
Joseph F. Murphy Trends in Cancer Immunotherapy Clinical Medicine Insights: Oncology |
author_facet |
Joseph F. Murphy |
author_sort |
Joseph F. Murphy |
title |
Trends in Cancer Immunotherapy |
title_short |
Trends in Cancer Immunotherapy |
title_full |
Trends in Cancer Immunotherapy |
title_fullStr |
Trends in Cancer Immunotherapy |
title_full_unstemmed |
Trends in Cancer Immunotherapy |
title_sort |
trends in cancer immunotherapy |
publisher |
SAGE Publishing |
series |
Clinical Medicine Insights: Oncology |
issn |
1179-5549 |
publishDate |
2010-01-01 |
description |
Modulation of the immune system for therapeutic ends has a long history, stretching back to Edward Jenner's use of cowpox to induce immunity to smallpox in 1796. Since then, immunotherapy, in the form of prophylactic and therapeutic vaccines, has enabled doctors to treat and prevent a variety of infectious diseases, including cholera, poliomyelitis, diphtheria, measles and mumps. Immunotherapy is now increasingly being applied to oncology. Cancer immunotherapy attempts to harness the power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for cancer immunotherapy is to apply advances in cellular and molecular immunology and develop strategies that effectively and safely augment antitumor responses. |
url |
https://doi.org/10.4137/CMO.S4795 |
work_keys_str_mv |
AT josephfmurphy trendsincancerimmunotherapy |
_version_ |
1724862474444865536 |